Drug-eluting stents: cost versus clinical benefit.
The publication in January 2001 of the first-in-man results showing zero restenosis after sirolimus-eluting stent implantation produced enormous excitement in the cardiological community. The long-awaited tool—a safe, restenosis-proof, easy-to-use stent— had been found. It was not too long thereafter that paclitaxel-eluting stents also demonstrated their capability to decrease restenosis.
|Keywords||Blood Vessel Prosthesis Implantation/adverse effects/statistics & numerical data, Clinical Trials/statistics & numerical data, Coronary Restenosis/prevention & control, Cost-Benefit Analysis/*statistics & numerical data, Drug Implants/adverse effects/*economics/therapeutic use, Humans, Stents/adverse effects/*economics/statistics & numerical data, Treatment Outcome|
|Persistent URL||dx.doi.org/10.1161/01.CIR.0000078025.19258.28, hdl.handle.net/1765/13173|
Lemos, P.A., Serruys, P.W.J.C., & Sousa, J.E.. (2003). Drug-eluting stents: cost versus clinical benefit.. Circulation (Baltimore), 107(24), 3003–3007. doi:10.1161/01.CIR.0000078025.19258.28